Epigenetics-targeted drugs: current paradigms and future challenges
Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, Renhao Guo, Peng Bai, Shuang Liu, Tingting Li, Yutao Jiang, Shuang Wei, Zhijing Na, Xue Xiao, Da Li · 2024
Read Epigenetics-targeted drugs: current paradigms and future challenges by Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, Renhao Guo, Peng Bai, Shuang Liu, Tingting Li, Yutao Jiang, Shuang Wei, Zhijing Na, Xue Xiao, Da Li (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11627502.txt.
Description
Wanlin Dai and a large team review drugs that target epigenetics, in a 2024 paper. Epigenetics covers the systems that switch genes on and off without changing the DNA code itself. When those systems go wrong, they help drive many diseases, above all cancer.
Over the past two decades, many small-molecule drugs against epigenetic enzymes have reached care or trials. The review covers how these drugs were found and how they are used, across blockers, activators, degraders, and multi-target agents. It also names practical hurdles for wider use. The authors aim to guide future work on this treatment strategy.
Catalog record
| CREATOR | Wanlin Dai, Xinbo Qiao, Yuanyuan Fang, Renhao Guo, Peng Bai, Shuang Liu, Tingting Li, Yutao Jiang, Shuang Wei, Zhijing Na, Xue Xiao, Da Li |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 336 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |